Key Highlights
- ABVX shares rose 6.36% to $96.85 at Monday's close on September 28, 2026, while the Russell 2000 slipped 0.69%.
- Abivax is a clinical-stage biotechnology company listed in the United States and rooted in France.
- Its lead candidate in inflammatory disease is widely followed for its potential in ulcerative colitis.
- For a development-stage name, investor engagement tends to track the lead program and its expected milestones.
Shares of Abivax (NASDAQ:ABVX) ended Monday, September 28, 2026 higher by 6.36%, at $96.85. The clinical-stage biotech, listed in the United States and rooted in France, has drawn intense investor attention for its lead candidate in ulcerative colitis.
Latest Developments
ABVX shares advanced at Monday's close in a session when the major US indexes fell.
Abivax is a clinical-stage biotechnology company whose lead candidate in inflammatory disease is widely followed for its potential in ulcerative colitis.
Financial and Business Position
For a development-stage name of this kind, investor engagement tends to track the lead program and its expected milestones.
Rising long-term yields typically weigh on clinical-stage biotech, whose value rests on cash flows expected years into the future. Abivax, with a closely watched lead asset and an active market debate around its prospects, is exactly the kind of name that can benefit from that improved appetite even on a broadly negative day for equities.
Stock-Market Context
The major averages closed lower on Monday, with the S&P 500 at 7,683.69 (down 0.77%), the Dow at 51,481.51 (down 0.67%) and the Nasdaq Composite at 26,820.38 (down 0.92%). Small caps fell too, as the Russell 2000 shed 0.69%.
A rejected Iranian proposal kept US-Iran tensions elevated and oil firm, while the 10-year Treasury Yield pushed past 5.2% to its highest level in nearly two decades.
Liquidia (NASDAQ:LQDA), MBX Biosciences (NASDAQ:MBX) and other biotech names also finished higher.
A Lead Program Keeps the Focus
Abivax closed Monday higher in a market that fell. The lead ulcerative colitis program is the reason the stock draws sustained attention.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...